Emerging Markets Earnings Roundup: AstraZeneca (Part 6)
This article was originally published in PharmAsia News
Executive Summary
Continuing double-digit growth in China, AstraZeneca reports strong performance for its Pulmicort, amid rival GSK’s 56% decline for its bestselling Advair/Seretide. Does GSK’s pain mean AstraZeneca’s gain?